CytoDyn Inc. (CYDY)

0.1501 -0.0049 (-3.16%) At close: 03:58PM EDT

CytoDyn Inc.

1111 Main Street
Suite 660
Vancouver, WA 98660
United States
360 980 8524
https://www.cytodyn.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 12

Key executives

Name	Title	Pay	Exercised	Year born
Dr. Cyrus Arman M.B.A., Ph.D.	Senior Vice President of Business Operations	451.17k	N/A	1982
Dr. Jacob P. Lalezari M.D.	CEO & Member of Scientific Advisory Board	N/A	N/A	1960
Mr. Mitchell Cohen	Interim Chief Financial Officer	N/A	N/A	1957
Mr. Tyler Blok	Executive Vice President of Legal Affairs & Secretary	N/A	N/A	1988
Dr. Scott Hansen Ph.D.	Head of Research & Basic Science	N/A	N/A	N/A
Mr. Joseph Meidling	Executive Director of Clinical Operations	N/A	N/A	N/A
Ms. Cristina De Leon	Investors	N/A	N/A	N/A

Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

CytoDyn Inc., a clinical-stage biotechnology company, engages in the development of treatments for multiple therapeutic indications. The company is involved in the clinical development of leronlimab, a novel humanized monoclonal antibody targeting the C-C chemokine receptor type 5 receptor in the areas of COVID-19, human immunodeficiency virus (HIV), Metabolic dysfunction-associated steatohepatitis (MASH), and solid tumors in oncology, such as metastatic triple-negative breast cancer. Its leronlimab is currently under phase 2 development for the treatment of NASH, HIV- NASH, and solid tumors, as well as under pre-clinical development for the treatment of HIV-PrEP and HIV-Cure. The company was formerly known as RexRay Corporation. CytoDyn Inc. was incorporated in 2002 and is based in Vancouver, Washington.

Corporate governance

CytoDyn Inc.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.